Andrew Sklawer

Andy Sklawer has over 17 years of experience in building and operating development-stage companies.

Prior to co-founding Brickell, he served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company acquired by Kadmon Corporation in 2011. Prior to Concordia, Mr. Sklawer held various positions with increasing responsibility at Verid, Inc., a developer of security technology prior to and subsequent to its acquisition by EMC Corporation.

Mr. Sklawer holds a B.S. degree in Marketing from the University of Florida and received his M.B.A. from the University of Miami. Andy currently serves as a Board Member for the Colorado Biosciences Association, StartUp FUI, and is on the Advisory Committee of the Advancing Innovation in Dermatology Accelerator Fund.